MediciNova's Ibudilast Reduces Retinal Thinning in MS Trial Subjects

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Nov 25, 2020 at 10:53 AM.

  1. #1 cafead, Nov 25, 2020 at 10:53 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,044
    Likes Received:
    3
    via MediciNova announced today that it received positive Optical Coherence Tomography (OCT) results from its SPRINT-MS Phase IIb trial of MN-166 (ibudilast) in multiple sclerosis (MS) subjects. The results were published in the Multiple Sclerosis Journal.

    article source
     
    Quote

Reply to Thread